Ophthalmogenetics and Gene Therapy

Ophthalmic hereditary qualities are worried about the hereditary commitment to ophthalmic illness, including assurance of examples and dangers of legacy, and in addition finding, visualization, and advancement of medications for hereditary variations from the norm. The advances in gene therapy maintain extensive promise for the cure of ophthalmic conditions. Gene therapy is additionally in a position to deal with primary open-angle glaucoma (POAG) in animal models, and research show it is economically viable. Genes may additionally be delivered into cells in vitro or in vivo making use of viral or non-viral vectors. Recent technical advances have led to the demonstration of the molecular basis of a range of ocular diseases.

  • Genetics of Myopia Development
  • Gene Therapy
  • Usher syndrome
  • Familial exudative vitreal retinopathy
  • Retinoblastoma
  • Leber hereditary optic neuropathy (LHON)
  • Optic atrophy
  • Genetics of Myopia Development

Related Conference of Ophthalmogenetics and Gene Therapy

September 16-17, 2025

20th International Conference on Ophthalmology and Vision Science

Amsterdam, Netherlands
September 22-23, 2025

8th International Eye and Vision Congress

Amsterdam, Netherlands
October 20-21, 2025

6th World Congress on Ophthalmology and Vision Science

Barcelona, Spain
November 03-04, 2025

39th European Ophthalmology Congress

Rome, Italy
January 12-13, 2026

26th Global Ophthalmologists Annual Meeting

London, UK
April 20-21, 2026

3rd International Conference on Ophthalmology

Barcelona, Spain
May 07-08, 2026

7th International Conference on Optometry

Paris, France
May 25-26, 2026

10th World Congress on Eye and Vision

Madrid, Spain

Ophthalmogenetics and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in